Navigation Links
Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661232/Osteoporosis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global osteoporosis therapeutics market. The report identifies the key trends shaping and driving the global osteoporosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoporosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
2. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
3. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
4. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
5. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
6. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
7. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
8. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
9. Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease
10. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
11. $1,700,000 Funding of NeoStems Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of #MedicareMonday ... remind you about some of our Medicare resources and continue highlighting the success of ... Check out our latest infographics and videos here: ... ... ...
(Date:7/30/2015)... Calif., July 30, 2015  Amgen (NASDAQ: ... second quarter of 2015. Key results include: ... second quarter of 2014 to $5,370 million, with ... Enbrel ® (etanercept), Prolia ® (denosumab), ... and XGEVA ® (denosumab). Unfavorable changes in ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... 5, 2011 Xlumena, Inc., a ... endoscopist and endoscopic surgeon, announced today that it ... AXIOS™ Stent and Delivery System (AXIOS). The AXIOS ... translumenal therapy and is indicated for drainage of ...
... May 5, 2011 A new position ... and Interventions (SCAI) calls for changes in the way ... angioplasty) care is measured and publically reported. The position ... published online in Catheterization and Cardiovascular Interventions ...
Cached Medicine Technology:Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System 2SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs 2SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs 3
(Date:8/1/2015)... CA (PRWEB) , ... August 01, 2015 , ... Have you ever wondered what “Karma” ... when you hear the word “Karma.” , Vedic tradition, which gave birth to Hinduism, ... is one of the central concepts of this tradition. According to the wisdom of this ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional Orthopedic ... company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 locations ... clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional as ...
(Date:8/1/2015)... ... ... 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) ... Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles in ... friends and family. He visited CCAR and left an inspirational message to his staff: ...
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, ... Bowl. In the two weeks that separate the conference championships and the Super Bowl, there ... game will mark the 50th time it has been held and the festivities will take ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On ... on October 3, 2015. The Ride to Fight On is a cycling fundraiser that ... Healthcare, The West Clinic and The University of Tennessee Health Science Center. A health ...
Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... researchers say estrogen may provide protection against colon cancer. ... to female mice and followed their progress for one year. ... ingredients. ,Diet one contained milk protein, and diet two ... The other three diets contained soy protein with the addition ...
... with clozapine and olanzapine may be at an ... taking these antipsychotic agents resisted insulin // and ... taking another drug under study. ,Researchers evaluated ... who were treated with clozapine (Clozaril), olanzapine (Zyprexa, ...
... quality of life they will have, say researchers according ... in the study . Researchers measured health-related quality of ... and child self-report to assess the physical, emotional, social ... percent of the children studied were not overweight; about ...
... disease has been debated for many years. A recent study shows ... migraine headaches report more chest pain, also known as angina. ... -- seeing what appears to be spots or lines in front ... of chest pain than those without a history of headaches. This ...
... common problem among critically ill patients, regardless of ... can be caused by a number of factors, ... or even some nutritional supplements. Previous studies have ... ,Researchers investigated more than 1,800 consecutive patients admitted ...
... between the level of sex hormones and an increased risk ... hormones estrogen and progesterone play a key role in breast ... cells, receiving and interpreting messages sent by the hormones. Estrogen ... as some breast cancer cells. Previous research has shown a ...
Cached Medicine News:
... specifically designed to work with the EC120 ... a small tank blotter that incorporates the ... buffer requirements and fast transfer rates), with ... blotting such as arcing and buffer depletion. ...
... The XCell II Blot Module allows you to ... to membranes. It fits neatly into the XCell ... the gel/buffer core assembly. It requires less than ... and northern transfers. Tough platinized titanium and stainless ...
... The GENIE is the proven electrophoretic transfer ... ultimate in field uniformity. Its design allows ... electrodes which, when coupled with a low ... charger, creates a high field in volts/cm. ...
Semi-Dry Blotting Unit for 10 x 10cm Gels...
Medicine Products: